More importantly, loss of PDLIM2 in lung tumors contributes to immune evasion, reduced MHC-I expression, increased chemoresistance, and activation of survival pathways, including upregulation of multidrug resistance genes like MDR1, promoting lung cancer and its therapy resistance [8–11]. This evidence concerns the gene PDLIM2 and lung cancer.